UA85996C2 - Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору - Google Patents

Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору

Info

Publication number
UA85996C2
UA85996C2 UA20041109788A UA20041109788A UA85996C2 UA 85996 C2 UA85996 C2 UA 85996C2 UA 20041109788 A UA20041109788 A UA 20041109788A UA 20041109788 A UA20041109788 A UA 20041109788A UA 85996 C2 UA85996 C2 UA 85996C2
Authority
UA
Ukraine
Prior art keywords
domain
tissue factor
fusion proteins
anticoagulants
thrombomodulin
Prior art date
Application number
UA20041109788A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дэвид Лайт
Кирк Маклин
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85996(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of UA85996C2 publication Critical patent/UA85996C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Данное изобретение касается новых слитых антикоагулянтных белков, которые включают белок, обеспечивающий направленное перенесение и взаимодействует с тканевым фактором (TF) или комплексом фактора VIIa/TF, а именно связывает TF или комплекс VIIa/TF, и какой функционально связан с тромбомодулиновым (ТМ) доменом EGF456 или его аналогами, и с доменом ТМ, который включает междоменную петлю между EGF3 и EGF4. Слитый белок связывается в участке повреждения и предотвращает инициацию тромбоза. Слитый белок может применяться для терапии разных тромбозных состояний, включая тромбоз глубоких вен, коагулопатию потребления и острый коронарный синдром.
UA20041109788A 2002-05-01 2003-04-30 Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору UA85996C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01

Publications (1)

Publication Number Publication Date
UA85996C2 true UA85996C2 (ru) 2009-03-25

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
UA20041109787A UA81114C2 (en) 2002-05-01 2003-04-30 Novel antibodies to tissue factor as anticoagulants
UA20041109788A UA85996C2 (ru) 2002-05-01 2003-04-30 Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UA20041109787A UA81114C2 (en) 2002-05-01 2003-04-30 Novel antibodies to tissue factor as anticoagulants

Country Status (29)

Country Link
US (3) US7250168B2 (ru)
EP (2) EP1549341B1 (ru)
JP (2) JP4460443B2 (ru)
KR (2) KR101080587B1 (ru)
CN (2) CN100563709C (ru)
AR (1) AR039515A1 (ru)
AT (2) ATE484524T1 (ru)
AU (2) AU2003225256B2 (ru)
BR (2) BR0304660A (ru)
CA (2) CA2483909A1 (ru)
CR (1) CR7584A (ru)
DE (2) DE60334538D1 (ru)
DK (2) DK1549341T3 (ru)
EC (2) ECSP045467A (ru)
ES (2) ES2354419T3 (ru)
HK (1) HK1080372A1 (ru)
IL (3) IL164733A0 (ru)
MX (2) MXPA04010851A (ru)
NO (2) NO20035848L (ru)
NZ (2) NZ536242A (ru)
PE (1) PE20040597A1 (ru)
PL (2) PL210582B1 (ru)
PT (2) PT1503785E (ru)
RS (2) RS102404A (ru)
RU (2) RU2345789C2 (ru)
TW (1) TWI343388B (ru)
UA (2) UA81114C2 (ru)
WO (2) WO2003092602A2 (ru)
ZA (2) ZA200409694B (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60043728D1 (de) * 1999-06-02 2010-03-11 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
AU2001296305B2 (en) 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
PE20040597A1 (es) * 2002-05-01 2004-10-06 Schering Ag Proteinas de fusion de trombomodulina dirigidas al factor tisular como anticoagulantes
EP1539235A2 (en) * 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
PL1745062T3 (pl) 2004-04-22 2014-10-31 Regado Biosciences Inc Ulepszone modulatory czynników krzepnięcia
EP1889908A4 (en) 2005-06-03 2012-04-25 Mochida Pharm Co Ltd PROTEIN FUSED WITH ANTI-CD14 ANTIBODY
WO2008039206A2 (en) * 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
WO2007115953A1 (en) * 2006-04-07 2007-10-18 Novo Nordisk Health Care Ag Covalent factor vii-tissue factor complex
CN101500608A (zh) 2006-06-08 2009-08-05 中外制药株式会社 炎性疾病的预防或治疗药
RU2433829C2 (ru) * 2006-10-06 2011-11-20 Асахи Касеи Фарма Корпорейшн Средство для лечения и/или улучшения состояния при диссеминированном внутрисосудистом свертывании
WO2008121814A1 (en) 2007-03-28 2008-10-09 Ats Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
WO2009037297A2 (en) * 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
US8333973B2 (en) * 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CN102171237A (zh) * 2008-08-14 2011-08-31 默沙东公司 使用蛋白a亲和色谱法纯化抗体的方法
US20110262466A1 (en) * 2008-10-16 2011-10-27 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
CA2771328A1 (en) * 2009-08-28 2011-03-03 Bayer Healthcare Llc Cofactors for thrombin activation of factor vii and uses thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
MX348567B (es) 2010-06-04 2017-06-20 Tiumbio Co Ltd Proteina de fusion que tiene actividad de factor vii.
RS56599B1 (sr) 2010-06-15 2018-02-28 Genmab As Konjugati humanog antitela sa lekom protiv tkivnog faktora
KR20130099027A (ko) * 2010-08-05 2013-09-05 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 혈전용해 및 응고억제 특성을 갖는 단백질 융합 구조물
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
WO2016176440A2 (en) * 2015-04-28 2016-11-03 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein c activators
WO2017189943A1 (en) * 2016-04-28 2017-11-02 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
PE20190966A1 (es) * 2016-11-16 2019-07-08 Bayer Healthcare Llc Factor viii direccionado a los globulos rojos y metodo para su uso
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
EP3861127A1 (en) * 2018-10-04 2021-08-11 Thrombosis and Coagulation AB Method for the determination of protein s levels
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha PHARMACEUTICAL PREPARATION COMPRISING AN ANTIBODY
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4912207A (en) * 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
KR920701459A (ko) * 1989-02-17 1992-08-11 코돈 트롬보모듈린의 가용성 유사체
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
US5466668A (en) * 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
KR930008093B1 (ko) * 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
BR9909382A (pt) * 1998-04-03 2000-12-05 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
JP2003527861A (ja) * 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
US6632791B1 (en) * 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
EP1465998A2 (en) 2002-01-08 2004-10-13 Bayer HealthCare AG Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
PE20040597A1 (es) 2002-05-01 2004-10-06 Schering Ag Proteinas de fusion de trombomodulina dirigidas al factor tisular como anticoagulantes

Also Published As

Publication number Publication date
RU2345789C2 (ru) 2009-02-10
CN100563709C (zh) 2009-12-02
RU2004135308A (ru) 2005-08-10
AU2003225255A1 (en) 2003-11-17
RU2004135306A (ru) 2005-07-10
KR101013697B1 (ko) 2011-02-10
MXPA04010851A (es) 2005-02-14
EP1549341A4 (en) 2006-10-18
DK1549341T3 (da) 2009-07-06
CR7584A (es) 2006-05-30
BR0304659A (pt) 2004-09-21
ES2323056T3 (es) 2009-07-06
US20080019985A1 (en) 2008-01-24
US7250168B2 (en) 2007-07-31
PL210582B1 (pl) 2012-02-29
CN1665534A (zh) 2005-09-07
PT1549341E (pt) 2009-05-29
US7622122B2 (en) 2009-11-24
US20080020965A1 (en) 2008-01-24
CA2483910A1 (en) 2003-11-13
PL373945A1 (en) 2005-09-19
CA2483909A1 (en) 2003-11-13
PL373960A1 (en) 2005-09-19
ECSP045467A (es) 2005-01-28
RS104504A (sr) 2007-02-05
BR0304660A (pt) 2005-06-07
JP4460443B2 (ja) 2010-05-12
IL164732A0 (en) 2005-12-18
KR20050045945A (ko) 2005-05-17
AU2003225256B2 (en) 2009-06-04
WO2003093422A2 (en) 2003-11-13
DE60326970D1 (de) 2009-05-14
RS102404A (sr) 2006-12-15
ZA200409694B (en) 2006-02-22
IL164733A0 (en) 2005-12-18
MXPA04010795A (es) 2005-03-07
ES2354419T3 (es) 2011-03-14
AR039515A1 (es) 2005-02-23
EP1549341A2 (en) 2005-07-06
KR101080587B1 (ko) 2011-11-04
WO2003092602A3 (en) 2004-08-26
ATE427121T1 (de) 2009-04-15
IL164733A (en) 2011-05-31
TWI343388B (en) 2011-06-11
EP1503785A2 (en) 2005-02-09
TW200307043A (en) 2003-12-01
AU2003225255B2 (en) 2008-07-31
JP2005538046A (ja) 2005-12-15
HK1080372A1 (zh) 2006-04-28
ZA200409692B (en) 2006-07-26
ATE484524T1 (de) 2010-10-15
ECSP045468A (es) 2005-01-28
JP2005532045A (ja) 2005-10-27
NO20035848L (no) 2004-02-27
EP1549341B1 (en) 2009-04-01
NZ536242A (en) 2006-04-28
DE60334538D1 (de) 2010-11-25
NZ536243A (en) 2006-06-30
CN100412090C (zh) 2008-08-20
DK1503785T3 (da) 2011-02-07
KR20050045944A (ko) 2005-05-17
NO20035849L (no) 2004-02-27
PE20040597A1 (es) 2004-10-06
WO2003093422A3 (en) 2004-07-15
UA81114C2 (en) 2007-12-10
CN1665526A (zh) 2005-09-07
JP4567437B2 (ja) 2010-10-20
RU2320366C2 (ru) 2008-03-27
US20040063632A1 (en) 2004-04-01
EP1503785A4 (en) 2007-02-14
US7622457B2 (en) 2009-11-24
AU2003225256A1 (en) 2003-11-17
EP1503785B1 (en) 2010-10-13
PT1503785E (pt) 2011-01-17
WO2003092602A2 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
UA85996C2 (ru) Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору
DE69225426D1 (de) Neue Thrombin-Inhibitoren
DE60238782D1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
PT1187918E (pt) Antagonistas de tek
NO20060466L (no) Variable antibodies
WO2002083849A3 (en) Vascular endothelial growth factor 2
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
NO20033839L (no) Transplantatrejeksjonssuppressorer
EP2228389A3 (en) Antibodies against vascular endothelial growth factor 2
DK1974615T3 (da) Proteingeldannelse
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
WO2006119035A3 (en) Vegf variants
MXPA05007689A (es) Tratamiento de enfermedades con agonistas completos del receptor alfa-7 de nach.
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
DK1194528T3 (da) Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
WO2003039491A3 (en) Novel isoforms of vascular endothelial cell growth inhibitor
NO20026286D0 (no) Nye peptider
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
WO2004074491A3 (en) Expression in plants of antibodies against enterotoxigenic escherichia coli
EA199800819A1 (ru) Способ лечения биполярного расстройства
WO2005058243A3 (en) Methods for treating cancer using vascular endothelial cell growth inhibitor vegi-192a
DE50200864D1 (de) Verbundelemente enthaltend bitumen
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
Engesser et al. 221 Impaired stimulation of t-PA mediated plasminogen activation and decreased binding of t-PA in a congenital dysfibrinogenemia